Keywords: novo, nordisk, sales, up, eps, rises, denmark
Novo Nordisk sales up 11%, EPS rises 19%
Article | 16 May 2005
Denmark's Novo Nordisk posted a solid set of first-quarter 2005 results, with sales up 11% at 7.26 billion Danish kroner, net profit rising 17% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
